Bruker BioSciences Reports Strong Revenue and Net Income Growth in the Second Quarter of 2007
BILLERICA, Mass.--(BUSINESS WIRE)--July 31, 2007--
Bruker BioSciences Corporation (NASDAQ: BRKR) today reported financial results for the three and six months ended June 30, 2007.
For the second quarter of 2007, revenue increased by 21% to $121.7 million, compared to revenue of $100.5 million in the second quarter of 2006. Excluding the effects of foreign currency translation, second quarter 2007 revenue increased by 17% year-over-year. Net income in the second quarter of 2007 was $5.0 million, or $0.05 per diluted share, compared to net income of $2.5 million, or $0.02 per diluted share, in the second quarter of 2006.
For the six months ended June 30, 2007, revenue increased by 19% to $232.2 million, compared to revenue of $195.3 million during the six months ended June 30, 2006. Excluding the effects of foreign currency translation, revenue for the six months ended June 30, 2007 increased by 14% year-over-year. Net income during the six months ended June 30, 2007 was $8.8 million, or $0.08 per diluted share, compared to net income of $5.8 million, or $0.06 per diluted share, during the six months ended June 30, 2006.
"The combination of our innovative products and solutions and favorable market dynamics enabled us to deliver solid increases in revenue and net income," said Frank Laukien, President and Chief Executive Officer, when commenting on the quarter. "We are very pleased with our second quarter 2007 year-over-year currency-adjusted revenue growth rate of 17%, which included an accelerating organic growth rate of 12% year-over-year. Moreover, new product introductions from both our core businesses and recent acquisitions have further strengthened our position as a leader in high-performance life-science and analytical systems, and have contributed to our very healthy backlog, which positions us well for the second half of 2007."
EARNINGS CONFERENCE CALL
Bruker BioSciences will host an operator-assisted earnings conference call at 9 a.m. Eastern Time on Tuesday, July 31, 2007. To listen to the webcast, investors can go to www.bruker-biosciences.com and click on the live web broadcast symbol. The webcast will be available through the Company web site for 30 days. Investors can also listen and participate on the telephone in the US and Canada by calling 888-339-2688, or 617-847-3007 outside the US and Canada. Investors should refer to the Bruker BioSciences Quarterly Earnings Call. A telephone replay of the conference call will be available one hour after the conference call by dialing 888-286-8010 in the US and Canada, or 617-801-6888 outside the US and Canada, and then entering replay pass code 72671589.
ABOUT BRUKER BIOSCIENCES
Bruker BioSciences Corporation in Billerica, Massachusetts is the parent company of Bruker AXS Inc., Bruker Daltonics Inc. and Bruker Optics, Inc. Bruker AXS is a leading developer and provider of life science, materials research and industrial X-ray analysis and spark-OES tools. Bruker Daltonics is a leading developer and provider of innovative life science tools based on mass spectrometry, and also offers a broad line of chemical, biological, radiological and nuclear (CBRN) detection products for homeland security. Bruker Optics is a leading developer, manufacturer and provider of research, analytical and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technology. For more information, please visit www.bruker-biosciences.com.
CAUTIONARY STATEMENT
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to our reorganization strategies, risks related to the integration of businesses we have acquired or may acquire in the future, technological approaches, product development, market acceptance, cost and pricing of our products, changes in governmental regulations, capital spending and government funding policies, FDA and other regulatory approvals to the extent applicable, competition, the intellectual property of others, patent protection and litigation. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our annual report on Form 10-K for the year ended December 31, 2006, our most recent quarterly reports on Form 10-Q and our current reports on Form 8-K. We disclaim any intent or obligation to update these forward-looking statements other than as required by law.
CONTACT:
Bruker BioSciences Corporation
Michael Willett, 978-663-3660, ext. 1411
Investor Relations Officer
Michael.Willett@Bruker.com
SOURCE:
Bruker BioSciences Corporation
